Meeting
2013 ASCO Annual Meeting
Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.
Authors
Nasser H. Hanna
Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN
Nasser H. Hanna , Rolf Kaiser , Richard N. Sullivan , Osvaldo Rudy Aren , Myung-Ju Ahn , Beatrice Tiangco , Zanete Zvirbule , Carlos H. Barrios , Ahmet Demirkazik , Birgit Gaschler-Markefski , Isabelle Voccia , Jose Barrueco , Joo-Hang Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00806819
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8034)
DOI
10.1200/jco.2013.31.15_suppl.8034
Abstract #
8034
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
First Author: Ignace Vergote
Poster
2018 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).
First Author: Hongyun Zhao
Poster
2023 ASCO Annual Meeting
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
First Author: Li Zhang
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino